



Why do we need CSF biomarkers in Alzheimer's disease (AD)?

			
Support diagnostic accuracy, particularly early in the disease course ¹	Confirm therapeutic target engagement and the effect of treatments on underlying pathology ¹	Provide surrogate measures of disease activity for monitoring and outcome evaluation ¹	Support patient stratification and enrichment of AD cases based on underlying pathology ¹

Biomarkers enhance diagnostic accuracy and physician

confidence²

In 2019, the Imaging Dementia Evidence for Amyloid Scanning (IDEAS) study published the first results showing that, by adding amyloid biomarkers like amyloid PET to the patient clinical assessment, diagnostic accuracy markedly improves.²



Roche's complete Alzheimer's disease portfolio

CSF analysis offers a direct, quantifiable, and accessible window into the brain's pathology. Roche is proud to offer a comprehensive and fully automated CSF Alzheimer's disease biomarker portfolio, covering the three key pillars of AD pathology.^{3,4,5,6,7}

AD Pathology	Pillar Roche Biomarker	Indication
Amyloid Plaque (A)	Elecsys® β -Amyloid (1-42) CSF II Elecsys® β -Amyloid (1-40) CSF*	Amyloid status (vs. PET)
Neurofibrillary Tangles (T)	Elecsys® Phospho Tau (181P) CSF	Tau pathology / Tangle formation
Neurodegeneration (N)	Elecsys® Total Tau CSF	Neuronal injury / Neurodegeneration

* Used in the β -Amyloid 42 / β -Amyloid 40 ratio to adjust for pre-analytical variability and optimize precision



Our complete portfolio ensures clinicians can capture the biological staging of Alzheimer's disease, delivering clarity and confidence in diagnosis.

[Discover more](#)

Contact

If you have additional questions, kindly contact your local Roche representative

Sincerely,
Roche Diagnostics International

References

1. Blennow K, et al. Fluid Biomarkers in Alzheimer's Disease. Cold Spring Harb Perspect Med. 2012;2:a006221.
2. Rabinovici GD, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019 Apr 2;321(13):1286-1294.
3. Jack CR Jr, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's Dement. 2024;20:5143-69.
4. Elecsys® beta Amyloid (1-42) CSF II Assay Method Sheet.
5. Elecsys® beta-Amyloid (1-40) CSF Assay Method Sheet.
6. Elecsys® Phospho-Tau (181P) CSF Assay Method Sheet.
7. Elecsys® Total-Tau CSF Assay Method Sheet



diagnostics. Roche . com

This email was sent by:

Roche Diagnostics International AG

Forrenstrasse 2, 6343 Rotkreuz, Switzerland

©2026 Roche Diagnostics Limited. All rights reserved.

[Manage profile](#)

[Privacy policy](#)

[Unsubscribe](#)

[Foward to a friend](#)

Roche Diagnostics Scandinavia AB, Box 1228, 171 23 Solna MC-SE-04624